Last edition
News about "olverembatinib"
Takeda Signs Option Deal with Ascentage Pharma to Get Exclusive Global License for Olverembatinib
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor.
Olverembatinib | 15/06/2024 | By Aishwarya | 122
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members